Prot# U2688s/NU G06H4: A Prospective, Randomized, Multi-Institutional Controlled, Open-Label, Phase II Pilot Trial of Rituximab Versus Oral Cyclophosphamide to Eradicate or Suppress Autoimmune Anti-Factor VIII Antibodies in Ptnts w/Acquired Hemophilia A

Project: Research project

Project Details

StatusFinished
Effective start/end date8/28/068/27/07

Funding

  • Georgetown University (U2688s/NU G06H4 // U2688s/NU G06H4)
  • Genentech, Inc (U2688s/NU G06H4 // U2688s/NU G06H4)